Idogen strengthens the organization before the clinical development phase

Idogen AB (publ) announces that the organization has been strengthened with several leading key roles before the company's most advanced drug candidate enters the clinical development phase. The management team is thus expanded with competence and experience in both early drug development and clinical trials.

In March 2022, Idogen received approval from the Medical Products Agency to initiate a clinical phase 1/2a study in the development program IDO 8, a potentially revolutionary cell therapy for patients with severe hemophilia A who have developed antibodies to their vital treatment with coagulation factor VIII. The study will be conducted at several testing centers in Europe and before the start, the company is now strengthening the organization with three new employees.

Idogen has appointed Hanjing Xie as Chief Medical Officer, CMO, with responsibility for the clinical development of the company's cell therapy treatment IDO 8. Hanjing Xie most recently came from Oncopeptides, where she was Senior Medical Study Director. She is a doctor and specialist in hematology, oncology and internal medicine and has over 20 years of clinical experience, mostly from Karolinska University Hospital, as well as extensive experience from clinical trials. She also has experience of clinical use of cell therapy treatments and is an associate professor at Karolinska Institutet. Hanjing Xie took office in January 2022.

Rory Graham has been appointed Chief Regulatory Officer, CRO, and will take up the post immediately. Rory Graham will continue the regulatory work on IDO 8 and additional applications to ensure the start of the planned Phase 1/2a study. He will also work to optimize the regulatory strategy in Europe and the United States to enable an efficient development process of IDO T, the company's drug candidate in the transplant field. Rory Graham has extensive experience of regulatory processes in both Europe and the United States, as well as extensive knowledge of cell therapies and biological drugs. He has worked at leading specialty pharma companies and smaller biotech companies.

Martina Johannesson has been recruited to the position of Program Manager Cell Therapy, with the task of ensuring coordination and implementation of the companies' two most advanced development programs, IDO 8 and IDO T. She most recently comes from the cell therapy company Amniotics, where she currently works as Preclinical Development Manager. Martina has extensive experience from cell therapy companies in terms of development processes and knowledge of GMP-certified manufacturing. Martina Johannesson will take office in July and will also take a seat on the management team.

“Before the start of our clinical phase 1/2a study with the drug candidate IDO 8, a new cell therapy in hemophilia, we strengthen the organization with several prominent people who have broad experience of clinical trials, regulatory work and cell therapies. That we have succeeded in attracting these abilities is both a proof of the solid science on which our drug candidates are based, but also the potential of our therapies in these difficult-to-treat diseases,”says Idogen's CEO Anders Karlsson.

In addition to Hanjing Xie, Rory Graham and Martina Johannesson, the management team consists of Anders Karlsson (CEO), Ingvar Karlsson (CFO), Åsa Schiött (CSO), Dennis Henriksen (CTO) and Neil Thomas (CBO and patent manager).

For further information, please contact:

Anders Karlsson, CEO, Idogen AB

Phone: +46 70 918 00 10

Email: anders.karlsson@idogen.com

Certified Adviser:
Erik Penser Bank AB, Box 7405, 103 91 Stockholm
Phone: +46 (0)8-463 80 00
Email: certifiedadviser@penser.se

The information was submitted for publication, through the agency of the contact persons set out above, on 13 April 2022 at 08:42 CET.

The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

Idogen (Nasdaq First Growth Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body's own cells or tissue. The company’s most advanced project, IDO 8, is designed to restore the efficacy of hemophilia drugs in patients who have developed neutralizing antibodies. The company’s second project, IDO T, is being developed to prevent kidney transplant rejection. In a third programme, IDO AID, Idogen is focused on the treatment of autoimmune diseases. The treatment for all indications is based on the patient's own cells and is expected to have a favorable safety profile and long-lasting effect. The potential for a short-term treatment intervention to yield a long-term effect is a major advantage in health economics for both patients and divisions providing care. More information about Idogen is available via https://www.idogen.com